-
Electronic (PDF)
-
Site License
-
Enterprisewide
Herpes Labialis (Oral Herpes) - Pipeline Review, Q2 2011
Global Markets Direct, May 2011, Pages: 42
Herpes Labialis (Oral Herpes) - Pipeline Review, Q2 2011
Summary
Global Markets Direct’s, 'Herpes Labialis (Oral Herpes) - Pipeline Review, Q2 2011', provides an overview of the Herpes Labialis (Oral Herpes) therapeutic pipeline. This report provides information on the therapeutic development for Herpes Labialis (Oral Herpes), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Herpes Labialis (Oral Herpes). 'Herpes Labialis (Oral Herpes) - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Herpes Labialis (Oral Herpes).
- A review of the Herpes Labialis (Oral Herpes) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Herpes Labialis (Oral Herpes) pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Herpes Labialis (Oral Herpes).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Herpes Labialis (Oral Herpes) pipeline depth and focus of Herpes Labialis (Oral Herpes) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Herpes Labialis (Oral Herpes) Overview
Therapeutics Development
An Overview of Pipeline Products for Herpes Labialis (Oral Herpes)
Herpes Labialis (Oral Herpes) Therapeutics under Development by Companies
Herpes Labialis (Oral Herpes) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Herpes Labialis (Oral Herpes) Therapeutics - Products under Development by Companies
Herpes Labialis (Oral Herpes) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Herpes Labialis (Oral Herpes) Therapeutics Development
BioAlliance Pharma SA
Nitric Biotherapeutics, Inc.
NanoBio Corporation
Beech Tree Labs, Inc.
EMS S.A.
Herpes Labialis (Oral Herpes) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles
BA-021 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NB-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Valacyclovir + Temovate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zicam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BTL-TML-HSV - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SPL7013 Gel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acyclovir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Penciclovir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Herpes Labialis (Oral Herpes) Therapeutics – Drug Profile Updates
Herpes Labialis (Oral Herpes) - Featured News
May 11, 2011: NanoBio And GSK Commence Phase III Studies Of Nanoemulsion-based OTC Treatment For Cold Sores
Feb 07, 2011: BioAlliance Pharma Presents Results Of International Survey Performed With Nielsen In Patients Suffering From Herpes Labialis
Nov 17, 2010: BioAlliance Pharma Presents Pharmacokinetic Results Of Sitavir At AAPS Annual Meeting
Nov 05, 2010: AiCuris To Present Preclinical And Phase I Data Of Anti-HSV Drug AIC316 At Antivirals Congress
Sep 14, 2010: Beech Tree Labs Initiates Phase I/IIa Oral Herpes Trial
Sep 07, 2010: BioAlliance Pharma Receives European Patent For Acyclovir Lauriad
Aug 26, 2010: BioAlliance Pharma Plans To Submit Acyclovir Lauriad NDA
Jul 07, 2010: Beech Tree Labs Wins FDA Approval For Oral Herpes IND Application
Oct 20, 2008: NanoBio's Topical Treatment NB-001 For Cold Sores Achieves Efficacy Of Oral Drugs; Represents Paradigm Shift In The Treatment Of Skin Infections
Feb 15, 2007: NanoBio Corporation Initiates Phase IIb Clinical Trial Of Its Drug Candidate NB-001 For Herpes Labialis Treatment
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Herpes Labialis (Oral Herpes), Q2 2011
Products under Development for Herpes Labialis (Oral Herpes) – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
BioAlliance Pharma SA, 2011
Nitric Biotherapeutics, Inc., 2011
NanoBio Corporation, 2011
Beech Tree Labs, Inc., 2011
EMS S.A., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Herpes Labialis (Oral Herpes) Therapeutics – Drug Profile Updates
List of Figures
Number of Products under Development for Herpes Labialis (Oral Herpes), Q2 2011
Products under Development for Herpes Labialis (Oral Herpes) – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW6
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
